GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1377-1382

  Hruz, Paul W ^a   Yan, Qingyun ^a   Tsai, Luong ^b   Koster, Joseph ^a   Xu, Lianhong ^b   Cihlar, Tomas ^b   Callebaut, Christian ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DEOXYGLUCOSE; GLUCOSE; GS 8374; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HUMAN INSULIN; INDINAVIR; INSULIN; LIPID; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; EUGLYCEMIC HYPERINSULINEMIC CLAMP; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADIPOCYTES; ANIMALS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HIV PROTEASE INHIBITORS; HOMEOSTASIS; HUMANS; INSULIN; MALE; MICE; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; RATS; RATS, WISTAR; RITONAVIR;

EID: 79953171167     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01184-10     Document Type: Article

References (25)

1. Ben-Romano, R., et al. 2004. Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta. Diabetologia 47:1107-1117. (Pubitemid 38918171)
2. Callebaut, C., et al. 2011. In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile. Antimicrob. Agents Chemother. 55:1366-1376.
3. Cihlar, T., et al. 2006. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring. J. Mol. Biol. 363:635-647.
4. Defronzo, R., J. Tobin, and R. Andres. 1979. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237:E214-E223.
5. Fernández-Montero, J., P. Barreiro, and V. Soriano. 2009. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin. Pharmacother. 10:1615-1629.
6. Foisy, M., and J. Sommadossi. 1999. Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 721:239-247. (Pubitemid 29142346)
7. Hadigan, C., et al. 2001. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32:130-139.
8. Hertel, J., H. Struthers, C. Baird Horj, and P. Hruz. 2004. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J. Biol. Chem. 279:55147-55152.
9. Hruz, P., H. Murata, H. Qiu, and M. Mueckler. 2002. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 51:937-942. (Pubitemid 34438334)
10. Hruz, P., and Q. Yan. 2006. Tipranavir without ritonavir does not acutely induce peripheral insulin resistance in a rodent mode. J. Acquir. Immune Defic. Syndr. 43:624-625.
11. Koh, Y., et al. 2003. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47:3123-3129.
12. Lee, G., et al. 2006. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin. Infect. Dis. 43:658-660.
13. Lee, G., et al. 2004. Ritonavir acutely induces insulin resistance in healthy normal human volunteers. Antivir. Ther. 9:L6.
14. Lee, G., et al. 2007. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 21:2183-2190. (Pubitemid 350287216)
15. Martinez-Cajas, J., and M. A. Wainberg. 2007. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 76:203-221.
16. Murata, H., P. Hruz, and M. Mueckler. 2002. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16:859-863. (Pubitemid 34409009)
17. Murata, H., P. W. Kruz, and M. Mueckler. 2000. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275:20251-20254.
18. Noor, M. A., O. P. Flint, J. F. Maa, and R. A. Parker. 2006. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20:1813-1821.
19. Noor, M. A., J. F. Maa, M. F. Giordano, and S. L. Hodder. 2004. Abstr. XV Int. AIDS Conf., abstr. WePeB5874.
20. Palella, F. J., Jr, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
21. Physicians' Desk Reference. 2008. Physicians' desk reference. Medical Economics Company, Montvale, NJ.
22. Reddy, M., and M. Erion. 1998. Structure-based drug design approaches for predicting binding affinities of HIV1 protease inhibitors. J. Enzyme Inhib. 14:1-14. (Pubitemid 29017183)
23. Sadler, B. M., et al. 2001. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 15:1009-1018. (Pubitemid 32476668)
24. Schütt, M., J. Zhou, M. Meier, and H. Klein. 2004. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J. Endocrinol. 183:445-454. (Pubitemid 40057575)
25. Yan, Q., and P. Hruz. 2005. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J. Acquir. Immune Defic. Syndr. 40:398-403.